{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:32:04Z","timestamp":1778153524367,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["RD16\/0025\/0040"],"award-info":[{"award-number":["RD16\/0025\/0040"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3n Progreso y Salud, Junta de Andalucia","award":["PI-0550-2017"],"award-info":[{"award-number":["PI-0550-2017"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.antiviral.2020.104717","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T11:25:08Z","timestamp":1579778708000},"page":"104717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient"],"prefix":"10.1016","volume":"179","author":[{"given":"Ana Bel\u00e9n","family":"Lozano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Chueca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo","family":"de Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Fern\u00e1ndez-Fuertes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Collado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2020.104717_bib1","unstructured":"Andrea-Garnier, E., Marcellin, AG., Reliquet, V., et\u00a0al. Unpublished results. Bictegravir Virology Failure with Emergence of a Previously Unreported Mutation in the Integrase Gene."},{"key":"10.1016\/j.antiviral.2020.104717_bib2","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/jac\/dkz347","article-title":"Switching to bictegravir\/emtricitabine\/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V\/I","volume":"74","author":"Andreatta","year":"2019","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2020.104717_bib4","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"Daar","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.antiviral.2020.104717_bib5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2144\/000113370","article-title":"DIVEIN: a web server to analyze phylogenies, sequence divergence, diversity, and informative sites","volume":"48","author":"Deng","year":"2010","journal-title":"Biotechnology"},{"key":"10.1016\/j.antiviral.2020.104717_bib6","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2020.104717_bib7","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1128\/AAC.00157-11","article-title":"Dolutegravir (S\/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes","volume":"55","author":"Hightower","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2020.104717_bib8","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1056\/NEJMc1806554","article-title":"Failure of dolutegravir first-line ART with selection of virus carrying R263K and G118R","volume":"381","author":"L\u00fcbke","year":"2019","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2020.104717_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00157-17","article-title":"The R263K dolutegravir resistance-associated substitution progressively decreases HIV-1 integration","volume":"8","author":"Mespl\u00e8de","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.antiviral.2020.104717_bib10","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.antiviral.2020.104717_bib11","author":"Neogi"},{"key":"10.1016\/j.antiviral.2020.104717_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12977-018-0440-3","article-title":"Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir","volume":"15","author":"Oliveira","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2020.104717_bib13","article-title":"Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV","year":"2019","journal-title":"Depart. Health Human Serv."},{"key":"10.1016\/j.antiviral.2020.104717_bib14","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy332","article-title":"Virological failure in HIV to triple therapy with dolutegravir-based firstline treatment: rare but possible","volume":"6","author":"Pena","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.antiviral.2020.104717_bib15","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2020.104717_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12977-018-0420-7","article-title":"Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants","volume":"15","author":"Smith","year":"2018","journal-title":"Retrovirology"},{"key":"10.1016\/j.antiviral.2020.104717_bib17","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"issue":"12","key":"10.1016\/j.antiviral.2020.104717_bib18","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","article-title":"Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile","volume":"21","author":"Tsiang","year":"2016","journal-title":"Antimicrob. Agents Chemother. AAC"},{"key":"10.1016\/j.antiviral.2020.104717_bib19","unstructured":"Vanig, T., Marcellin, AG., Calvez, V., Unpublished Results. Selection of Integrase Inhibitor (INI) Resistance Mutations in an INI Experienced Patient Treated by Bictegravir."},{"key":"10.1016\/j.antiviral.2020.104717_bib20","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219307302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354219307302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:33:04Z","timestamp":1759062784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354219307302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":19,"alternative-id":["S0166354219307302"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104717","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Failure to bictegravir and development of resistance mutations in an antiretroviral-experienced patient","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2020.104717","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104717"}}